Over 60% of the total in the 50s and 60s… 36.2% of those in their 30s and 40s
As a result of an analysis of SK Bioscience’s general public offering, which has written a new history of public offering stock subscriptions, it was found that over 60s led the record for the largest margin ever.
According to NH Investment & Securities, the representative IPO of SK Biosciences on the 11th, in the general public offering of SK Biosciences held on the 9th to 10th, the combined proportion of 50s and 60s was found to be 60% of all subscribers. .
In particular, the proportion of investors in their 60s and older recorded 32%. It is an evaluation that the average subscription amount also accounts for about three times the overall average, proving that it is a’wang ant’.
By age, △32% in their 60s or older △28.1% in their 50s △22.54% in their 40s △13.72% in their 30s △3.12% in their 20s △0.46% in their teens and younger.
NH Investment & Securities explained that the results were different from SK Biopharm and Big Hit, which were in charge of last year. In the case of SK Biopharm, the proportion of investors in their 60s or older (17.81%) and 50s (22.17%) was only 40%. On the other hand, in the 30s and 40s, 26.94% of those in their 40s and 25.12% of those in their 30s were found to be more than half.
In the case of Big Hit, those in their 60s and above recorded 14.22%, and those in their 50s recorded 22.66%, respectively, which was also lower than that of those in their 30s and 40s (27.92% in their 40s and 25.09% in their 30s).
An official at NH Investment & Securities’ Wealth Management Strategy Department explained, “The increase in subscribers in their 60s and above is interpreted as a result of interest in public offering stocks with low risk and high profitability due to the recent sideways movement in the stock market, and changes in the allocation system for public offering stocks.”
On the other hand, customers who applied for 10 shares to NH Investment & Securities can be allocated at least 1 week, and customers who applied for about KRW 100 million (975 million KRW, 3,000 shares) will be allocated at least 5 weeks.
NH Investment & Securities, which is scheduled to be listed on the 18th of this month, if SK Bioscience, which is scheduled to be listed on the 18th of this month, records a’tasang’ (the public offering doubles and reaches the upper limit of up to 30%), investors will be able to make a profit of about 104,000 won per share, and the next day. If the upper limit is continued until, the valuation profit is expected to record about 154,000 won per share.
Copyright © Shin-A Ilbo Unauthorized reproduction and redistribution prohibited